Comparing Meridian Bioscience (VIVO) and CryoLife (CRY)

Meridian Bioscience (NASDAQ: VIVO) and CryoLife (NYSE:CRY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Volatility & Risk

Meridian Bioscience has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.


Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.5%. CryoLife does not pay a dividend. Meridian Bioscience pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. CryoLife has increased its dividend for 4 consecutive years.

Valuation & Earnings

This table compares Meridian Bioscience and CryoLife’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Meridian Bioscience $198.07 million 3.01 $52.80 million $0.51 27.75
CryoLife $183.16 million 4.04 $23.56 million $0.33 66.97

Meridian Bioscience has higher revenue and earnings than CryoLife. Meridian Bioscience is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

87.3% of Meridian Bioscience shares are held by institutional investors. Comparatively, 68.4% of CryoLife shares are held by institutional investors. 2.3% of Meridian Bioscience shares are held by company insiders. Comparatively, 6.0% of CryoLife shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Meridian Bioscience and CryoLife’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Meridian Bioscience 10.77% 16.93% 11.36%
CryoLife 6.16% 7.41% 4.95%

Analyst Ratings

This is a summary of recent ratings and target prices for Meridian Bioscience and CryoLife, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meridian Bioscience 1 3 0 0 1.75
CryoLife 0 0 3 0 3.00

Meridian Bioscience presently has a consensus price target of $14.33, indicating a potential upside of 1.30%. CryoLife has a consensus price target of $22.33, indicating a potential upside of 1.06%. Given Meridian Bioscience’s higher probable upside, analysts clearly believe Meridian Bioscience is more favorable than CryoLife.


Meridian Bioscience beats CryoLife on 9 of the 17 factors compared between the two stocks.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

CryoLife Company Profile

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply